Human Resources

Gen-Probe Incorporated (NASDAQ:GPRO) develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company develops nucleic acid testing that enables detection of microorganisms. It markets a portfolio of products that use technologies to detect various infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia, and fungal infections. The company also offers blood screening products for the simultaneous detection of human immunodeficiency virus (type 1), hepatitis C virus, and procleix west nile virus. In addition, it sells TIGRIS instrument that enables blood collection centers to test donors’ blood. Further, the company develops and manufactures nucleic acid probe-based products for the detection of harmful organisms in the environment and in industrial processes. It markets and sells its clinical diagnostic products through distributors and direct sales force, as well as other products through collaborative partners. The company’s customers include reference laboratories, public health institutions, and hospitals. It has a collaboration agreement with Novartis Vaccines and Diagnostics, Inc. for the research, development, and manufacturing of its blood screening products. Founded in 1983 and employing over 1200 people, Gen-Probe is headquartered in San Diego, CA and has additional offices/facilities in Stamford, CT, the United Kingdom and France.



Human Resources
10210 Genetic Center Drive
92121 San Diego, CA
Vereinigte Staaten von Amerika
Forschung & Lehre
Sonstige Tätigkeitsfelder
mehr als 500